ClinicalTrials.gg
RecruitingNCT06584097Updated Nov 5, 2026

COMparative Performance of General Purpose Models

An observational study in Neurosurgical Patients, sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta. Recruiting at 2 sites in Italy. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Observational

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.
Updated Nov 5, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
42
Sex
All
01

Study summary

To compare the performance of the Eleveld models for propofol and remifentanil on neurosurgery patients admitted to intensive care with their intraoperative performance.

Read the detailed description

Despite the widespread adoption of Target Controlled Infusion (TCI) models in modern clinical anesthesia practice, much less attention has been paid in the literature to their potential applications in the Intensive Care Unit (ICU) setting. Few studies have been published so far to evaluate the performance of TCI pumps for sedatives and other drugs (e.g., antibiotics) in Intensive Care. Further data is needed regarding the use of TCI for the long-term infusion of these drugs in the ICU after surgery, and the quantitative relationship between generalized pharmacokinetic/pharmacodynamic models for propofol and remifentanil (the Eleveld models) has yet to be evaluated in this specific population. This study is an observational study with the aim of clarifying the predictive performance of the TCI models for the administration of propofol and remifentanil in a cohort of intensive care patients admitted after neurosurgery and compare it to the intraoperative performance, which can be taken as benchmark.

02

Conditions studied

  • Neurosurgical Patients

Keywords

  • Neuroanesthesia
  • total intravenous anesthesia
  • target controlled infusion
  • PKPD modelling
03

In context

Lead sponsor

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta is the lead sponsor of 84 studies on the registry; 32 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult patients undergoing elective neurosurgical procedures with an expected sedation after surgery of > 12 hours

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients undergoing elective neurosurgical procedures with an expected sedation after surgery of > 12 hours • Requirement for an arterial line

Exclusion criteria

Exclusion Criteria:

  • Pregnancy

    • Known sensitivity or allergy to propofol or remifentanil
    • Patient participating in research for which a period of exclusion is currently required by other study protocol, ethical committee or health authority.
    • Age \< 18 years old
    • Patients subjected to infusion of propofol and/or remifentanil not delivered through TCI pumps before the inclusion
    • Patients exposed to other sedatives (benzodiazepines, volatile anesthetics, quetiapine) before the inclusion
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
42 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. MdAPE difference for propofol

    The difference in MdAPE will be measured when comparing the model performance for propofol in the ICU to the intraoperative phase.

    Time frame: october 2024

  2. MdAPE difference for remifentanil

    The difference in MdAPE will be measured when comparing the model performance for remifentanil in the ICU to the intraoperative phase.

    Time frame: october 2024

Secondary outcomes

  1. Propofol and remifentanil metabolites

    Metabolites of propofol and remifentanil (4-hydroxy propofol and remifentanil acid) during infusion

    Time frame: october 2024

  2. BIS profile

    Bispectral index monitor profile during infusion (min = 0, max = 100)

    Time frame: october 2024

  3. NOL profile

    NOL (Nociceptive Level) value (min = 0, max = 100)

    Time frame: Oct 2024

  4. RASS

    RASS measurements during infusion (min = -5, max = +4).

    Time frame: october 2024

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Propofol and remifentanil pharmacokinetic and pharmacodynamic data.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2024
First posted
Sep 4, 2024
StartActual
Oct 2, 2024
Primary completionEst.
Dec 31, 2026was Oct 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 1, 2026→Dec 31, 2026
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Oct 1, 2026→Dec 31, 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06584097
Lead sponsor
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Responsible party
Sponsor
First posted
Sep 4, 2024
Start date
Oct 2, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 5, 2026

Study contacts

Michele Introna, M.D.
Contact
michele.introna@istituto-besta.it
00390223942420
Marco Gemma, M.D.
Contact
marco.gemma@istituto-besta.it
0039022394.2411
Michele Introna, M.d.
principal investigator · Fondazione IRCCS Istituto Neurologico C. Besta

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion